A systematic review of ovarian cancer and fear of recurrence.
OBJECTIVE
To assess demographic, medical, and psychological factors that are associated with fear of recurrence (FCR) in ovarian cancer patients.


METHODS
We searched PubMed, EMBASE, Cochrane, CINAHL, and PsycINFO. For PubMed, a search using Medical Subject Headings (MeSH) was run, as well as a text-word search from 1990 to July of 2014. The search terms used consisted of ovarian terms, fear terms, and recurrence/progression themes. Title and abstract reviews were conducted by two independent reviewers to determine eligibility, and discrepancies were decided by a third reviewer. Full-text reviews of potentially eligible articles were conducted by the review team, which met regularly to ensure the reliability of eligibility ratings across all articles.


RESULTS
A total of 15 articles met our inclusion criteria. Nine were quantitative studies that utilized a cross-sectional design, and the other six included three qualitative studies, two small intervention studies, and one study that utilized content analysis to explore written correspondence among ovarian cancer patients. FCR was reported as a significant concern for both older and younger women at both early and advanced stages. Women were distressed about recurrence at various times during their treatment and posttreatment. FCR was noted to be prevalent around cancer follow-up examinations. Many women reported not receiving adequate support for recurrence. FCR was also shown to be linked in some way to hopelessness, faith/spirituality, and posttraumatic stress disorder (PTSD). FCR was also linked to patients' anxiety about death and dying and uncertainty about the future of their medical health.


CONCLUSIONS
This review demonstrates that FCR is prevalent in the ovarian cancer population. Moreover, cancer recurrence fears are not adequately assessed or treated. More information is needed on the factors that may be related to women's fears about recurrence of ovarian cancer. In addition, a validated measure of FCR among ovarian cancer patients as well as a treatment intervention are needed.
Memorial Sloan Kettering Cancer Center,New York,New York.
Melissa
M
Ozga
Memorial Sloan Kettering Cancer Center,New York,New York.
Carol
C
Aghajanian
Temple University and Rutgers Cancer Institute of New Jersey,New Brunswick,New Jersey.
Shannon
S
Myers-Virtue
Memorial Sloan Kettering Cancer Center,New York,New York.
Glynnis
G
McDonnell
Memorial Sloan Kettering Cancer Center,New York,New York.
Sabrina
S
Jhanwar
Memorial Sloan Kettering Cancer Center,New York,New York.
Shira
S
Hichenberg
Memorial Sloan Kettering Cancer Center,New York,New York.
Isabel
I
Sulimanoff
D001007:Anxiety / Q000523:psychology; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005239:Fear / Q000523:psychology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000150:complications / Q000523:psychology*; D012008:Recurrence; D017741:Survivors / Q000523:psychology*
FCR; Fear of recurrence; Ovarian cancer; Recurrence/progression